Abstracts tagged "cyclophosphamide"

Abstract Number: 886 • 2015 ACR/ARHP Annual Meeting
Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis
Sophia Lionaki¹, George Fragoulis², Aliki Venetsanopoulou², Panayiotis Vlachoyiannopoulos², John Boletis¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas², ¹Nephrology, Laiko Hospital, Department of Nephrology, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: To evaluate the long term outcomes, of patients with multi-relapsing Antineutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis (AAV), who received induction therapy with a rituximab…
Abstract Number: 1075 • 2015 ACR/ARHP Annual Meeting
The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
Philip J. Clements¹, Donald Tashkin¹, Michael Roth¹, Dinesh Khanna², Daniel E. Furst³, Chi-hong Tseng¹, Elizabeth R. Volkmann¹ and Robert Elashoff⁴, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomath, University of California Los Angeles, David Geffen School Of Medicine, Los Angeles, CA
Background/Purpose: Demonstrate that the course of forced vital capacity (FVC) over 2-years was better in SSc patients with symptomatic ILD treated with oral MMF for…
Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Michael Roth², Robert Elashoff³, Philip J. Clements¹, Daniel E. Furst², Dinesh Khanna⁴, Jonathan Goldin⁵, Donald Tashkin¹ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…
Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting
Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea
Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
Abstract Number: 1799 • 2015 ACR/ARHP Annual Meeting
IgG Levels Correlate Inversely with Proteinuria Among Participants in the Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Trial, but Hypogammaglobulinemia Was Not Associated with an Increased Risk of Serious Infection
Sara G. Murray¹, Noha Lim², Michael Stahly², Dawn Smilek³ and David Wofsy⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Immune Tolerance Network, Bethesda, MD, ³Immune Tolerance Network, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Hypogammaglobulinemia has been associated with serious infectious adverse events (SIAE) and may occur during immunosuppressive therapy for lupus nephritis (LN). It is possible that…
Abstract Number: 1818 • 2015 ACR/ARHP Annual Meeting
Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis
Shubhasree Dutta Choudhury¹, Ann Biehl², Maryam Ghaderi-yeganeh³, Zerai Manna⁴ and Sarfaraz Hasni⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases2, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institutes of Health Clinical Center Department of Pharmacy, National Institutes of Health, Bethesa, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Immune dysregulation associated with SLE leads to a substantially high background risk of infection. This risk of infection further increases with the use of…
Abstract Number: 2371 • 2015 ACR/ARHP Annual Meeting
The Clinical Features of Recurrent Interstitial Lung Disease in Dermatomyositis Patients with Anti- Melanoma Differentiation-Associated Gene 5 Antibody
Yuji Hosono¹, Ran Nakashima¹, Kosaku Murakami², Yoshitaka Imura², Naoichiro Yukawa², Hajime Yoshifuji², Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Interstitial lung disease (ILD) is the most common cause of mortality in polymyosytis (PM) and dermatomyositis (DM). It is well known that the DM…
Abstract Number: 2921 • 2015 ACR/ARHP Annual Meeting
Lupus Nephritis: An Exploration of Management Style
Abhishek Nandan¹, Huzaefah Syed², Christen Vagts¹ and Jason Kidd¹, ¹Virginia Commonwealth University Medical Center, Richmond, VA, ²Rheumatology, Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: We aim to evaluate the differences and rationale behind the diagnostic and therapeutic approaches to proliferative lupus nephritis (LN) among nephrologists and rheumatologists. Methods:…
Abstract Number: 2941 • 2015 ACR/ARHP Annual Meeting
Outcomes in Lupus Nephritis Patients Previously Randomized to Receive Either Low Dose Cyclophosphamide Versus Oral Mycophenolate Mofetil on Azathioprine Maintenance
Manish Rathi¹, Ajay Jaryal², Ajay Goyal², Aman Sharma³, Pramod Gupta⁴ and Krishan Gupta², ¹Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴Biostatistics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Management of SLE and lupus nephritis is challenging as it is always a trade off between remission, prevention of relapse and long term adverse…
Abstract Number: 2962 • 2015 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
Javier Narváez¹, Helena Borrell Paños², Ivan Castellvi³, Sergi Heredia², Milena Millan³, Susana Herrera⁴, Eulalia Armengol², Josep María LLobet³, Joan Miquel Nolla², María Molina⁵ and Juan José Alegre⁶, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, ⁵Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Background/Purpose: Treatment with cyclophosphamide (CYC) for 12 months stabilizes lung function parameters and improves respiratory symptoms of patients with systemic sclerosis and diffuse interstitial lung…
Abstract Number: 1781 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years
Rennie L. Rhee¹, Susan L Hogan², Caroline J. Poulton², Julie Anne G. McGregor², J. Richard Landis³, Ronald Falk⁴ and Peter A. Merkel⁵, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²UNC Kidney Center, Chapel Hill, NC, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Dept of Nephrology and Hypertension, UNC Kidney Center, Chapel Hill, NC, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose Significant advances have been made in the diagnosis and treatment of patients with ANCA-associated vasculitis (AAV). However, little is known about how these advances…
Abstract Number: 1782 • 2014 ACR/ARHP Annual Meeting
Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Pascal Cohen², Boris Bienvenu⁴, Kim Heang Ly⁵, Alain Bruet⁶, Brigitte Gilson⁷, Marc Ruivard⁸, Edouard Pertuiset⁹, Mohamed Hamidou¹⁰, Benjamin Terrier², Christian Pagnoux¹¹, Luc Mouthon², Loic Guillevin¹² and The French Vasculitis Study Group (FVSG)¹², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Médecine interne, CHU Côte de Nacre, CAEN, France, ⁵CHU Dupuytren, Limoges, Limoges, France, ⁶Department of Nephrology and Internal Medicine, CH de Poissy Saint-Germain-en-Laye, Poissy, France, ⁷Department of Nephrology and Internal Medicine, CH de Verdun, Verdun, France, ⁸CHU Estaing, Clermont–Ferrand, Clermont–Ferrand, France, ⁹Rheumatology, René Dubos Hospital, Pontoise, France, ¹⁰CHU Hôtel Dieu, Nantes, Nantes, France, ¹¹Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose To study the long-term outcomes of 65 patients with non-HBV polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) enrolled in a prospective, randomized, open-label trial,1…
Abstract Number: 2675 • 2013 ACR/ARHP Annual Meeting
Phase 2 Trial On Triptorelin For Ovary Protection In Childhood-Onset Systemic Lupus Erythematosus
Rina Mina¹, Andreas Reiff², Clovis A. Silva³, Patricia Vega Fernandez⁴, Gloria C. Higgins⁵, Lisa F. Imundo⁶, Marisa S. Klein-Gitelman⁷, Calvin Williams⁸, Carol A. Wallace⁹, Nadia E. Aikawa¹⁰, Shannen L. Nelson¹¹, Jun Ying¹², Susan R. Rose¹³ and Hermine Brunner¹⁴, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Cincinnati Children's Hospital Medica Center, CINCINNATI, OH, ⁵Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ⁶Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ⁷Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁸Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ¹⁰Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹¹Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹²Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, ¹³Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴PRCSG, Cincinnati, OH
Background/Purpose: Gonadotoxicity is a known side effect of cyclophosphamide (CYC) therapy in childhood-onset systemic lupus erythematosus (cSLE). Gonadotropin releasing hormone (GnRH) agonists, such as triptorelin,…
Abstract Number: 1559 • 2013 ACR/ARHP Annual Meeting
Cyclophosphamide and Rituximab Combination Treatment For Severe Systemic Lupus erythematosus is Effective and Well Tolerated
Ali Shahzad¹, Farheen Jafri², Bisharah Rizvi², Xiongce Zhao³, Meryl Waldman³ and Sarfaraz A. Hasni⁴, ¹National Institute of Arthritis, Musculoskeletal and skin diseases, NIAMS/NIH, Bethesda, MD, ²R-Research, Hamilton, NJ, ³NIDDK/NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is often complicated by resistance or partial response to initial immunosuppressive regimen and flares after initial response. Optimal management of…
Abstract Number: 1255 • 2013 ACR/ARHP Annual Meeting
Ovarian Dysfunction In Adult Childhood-Onset Systemic Lupus Erythematosus Patients: A Possible Role Of Methotrexate?
Daniel B. Araujo¹, Lucas Yamakami², Eloisa Bonfá³, Vilma S. T. Viana⁴, Sandra G. Pasoto⁵, Rosa M. Pereira⁴, Paulo C. Serafin², Eduardo F. Borba⁶ and Clovis A. Silva⁷, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, ²Gynecology Department, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division; University of São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil
Background/Purpose: Reduction of ovarian reserve has been observed in childhood-onset SLE (c-SLE) and adult SLE populations, and most of them were limited to follicle stimulating…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].